Relief Therapeutics Holding AG (RLFTF)

[mc67]

$RLFTF and JJ/NeuroRx are well able.. The Mirabaud analyst had said he believed that Relief would need a larger pharmaceutical company to distribute the compound in addition to its partner NeuroRx.

Of course, Relief would have to cede part of the revenues to an additional partner.

But according to Selvaraju, no large commercial organization is necessary.

RLF-100 is not a mass product, but is administered in intravenous form in hospitals. The inhalable form, for which a study will start in the coming weeks, is intended for home use.

Relief already has well-established distribution channels for both, which it can use in case of approval.

If governments in the U.S. or other countries ordered the drug, Relief would not incur any marketing or distribution costs